🇺🇸 FDA
Patent

US 10093708

Interleukin-4 receptor-binding fusion proteins and uses thereof

granted A61KA61K38/00A61K38/1761

Quick answer

US patent 10093708 (Interleukin-4 receptor-binding fusion proteins and uses thereof) held by Medicenna Therapeutics Inc. expires Mon Oct 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Medicenna Therapeutics Inc.
Grant date
Tue Oct 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K38/00, A61K38/1761, A61K38/193, A61K38/2026